Adaptation to HIF1α Deletion in Hypoxic Cancer Cells by Upregulation of GLUT14 and Creatine Metabolism.


Journal

Molecular cancer research : MCR
ISSN: 1557-3125
Titre abrégé: Mol Cancer Res
Pays: United States
ID NLM: 101150042

Informations de publication

Date de publication:
07 2019
Historique:
received: 30 03 2018
revised: 28 01 2019
accepted: 13 03 2019
pubmed: 20 3 2019
medline: 2 5 2020
entrez: 20 3 2019
Statut: ppublish

Résumé

Hypoxia-inducible factor 1α is a key regulator of the hypoxia response in normal and cancer tissues. It is well recognized to regulate glycolysis and is a target for therapy. However, how tumor cells adapt to grow in the absence of HIF1α is poorly understood and an important concept to understand for developing targeted therapies is the flexibility of the metabolic response to hypoxia via alternative pathways. We analyzed pathways that allow cells to survive hypoxic stress in the absence of HIF1α, using the HCT116 colon cancer cell line with deleted HIF1α versus control. Spheroids were used to provide a 3D model of metabolic gradients. We conducted a metabolomic, transcriptomic, and proteomic analysis and integrated the results. These showed surprisingly that in three-dimensional growth, a key regulatory step of glycolysis is Aldolase A rather than phosphofructokinase. Furthermore, glucose uptake could be maintained in hypoxia through upregulation of GLUT14, not previously recognized in this role. Finally, there was a marked adaptation and change of phosphocreatine energy pathways, which made the cells susceptible to inhibition of creatine metabolism in hypoxic conditions. Overall, our studies show a complex adaptation to hypoxia that can bypass HIF1α, but it is targetable and it provides new insight into the key metabolic pathways involved in cancer growth. IMPLICATIONS: Under hypoxia and HIF1 blockade, cancer cells adapt their energy metabolism via upregulation of the GLUT14 glucose transporter and creatine metabolism providing new avenues for drug targeting.

Identifiants

pubmed: 30885992
pii: 1541-7786.MCR-18-0315
doi: 10.1158/1541-7786.MCR-18-0315
doi:

Substances chimiques

Glucose Transport Proteins, Facilitative 0
HIF1A protein, human 0
Hypoxia-Inducible Factor 1, alpha Subunit 0
SLC2A14 protein, human 0
Fructose-Bisphosphate Aldolase EC 4.1.2.13
Glucose IY9XDZ35W2
Creatine MU72812GK0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1531-1544

Subventions

Organisme : Medical Research Council
ID : MR/P010334/1
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RG/18/12/34040
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RG/13/8/30266
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C602/A18974
Pays : United Kingdom

Informations de copyright

©2019 American Association for Cancer Research.

Auteurs

Alessandro Valli (A)

Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom. alevalli14@gmail.com alessandro.valli@cardiologicomonzino.it.
Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

Matteo Morotti (M)

Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.

Christos E Zois (CE)

Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.

Patrick K Albers (PK)

The Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom.

Tomoyoshi Soga (T)

Institute for Advanced Biosciences, Keio University, Tsuruoka, Yamagata, Japan.

Katharina Feldinger (K)

Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.

Roman Fischer (R)

Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

Martin Frejno (M)

Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

Alan McIntyre (A)

Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.

Esther Bridges (E)

Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.

Syed Haider (S)

Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.

Francesca M Buffa (FM)

Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.

Dilair Baban (D)

The Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom.

Miguel Rodriguez (M)

Metabolomics Platform, IISPV, Department of Electronic Engineering, Universitat Rovira i Virgili, Tarragona, Spain.
Spanish Biomedical Research Center in Diabetes and Associated Metabolic Disorders-CIBERDEM, Madrid, Spain.

Oscar Yanes (O)

Metabolomics Platform, IISPV, Department of Electronic Engineering, Universitat Rovira i Virgili, Tarragona, Spain.
Spanish Biomedical Research Center in Diabetes and Associated Metabolic Disorders-CIBERDEM, Madrid, Spain.

Hannah J Whittington (HJ)

Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.

Hannah A Lake (HA)

Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.

Sevasti Zervou (S)

Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.

Craig A Lygate (CA)

Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.

Benedikt M Kessler (BM)

Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

Adrian L Harris (AL)

Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH